Onco-pneumology

Charlotte Germonpré is the study coordinator for the Pneumology Department.

Charlotte Germonpré

Telephone: +32 9 246 84 40

Email address: charlotte.germonpre@azmmsj.be

More information about Charlotte Germonpré

The Oncology-Pneumology Study Department is under the leadership of:

Dr Lamont Jan

More information about Dr Lamont Jan

Prof. Dr Germonpré Paul

More information about Prof. Dr Germonpré Paul

• CA224-104 study: A randomised phase-II trial of Relatlimab plus Nivolumab in combination with chemotherapy versus Nivolumab in combination with chemotherapy as first-line treatment for patients who have stage IV or recurrent non-small cell lung cancer. Read more here.
• Tropion-08 study: A randomised, open-label phase-III trial of Dato-DXd plus Pembrolizumab versus Pembrolizumab in previously untreated patients who have advanced or metastatic PD-L1-high (TPS ≥50%) non-small cell lung cancer without actionable genomic alterations. Read more here.
• Krystal-7 study: A phase-II study of MRTX849 in monotherapy and in combination with Pembrolizumab in patients who have advanced non-small cell lung cancer with KRAS G12C mutation. Read more here.
• Krystal-12 study: A randomised phase-III trial of MRTX849 compared with Docetaxel in patients who have previously treated non-small cell lung cancer with a KRAS G12C mutation. Read more here.
• M14-239 study: An open-label phase-II study on the safety and efficacy of Telisotuzumab Vedotin (ABBV-399) in c-Met positive patients who have non-small cell lung cancer. Read more here.